Norgine Successfully Completes Acquisition of Theravia to Expand Rare Disease Portfolio

Norgine’s Acquisition of Theravia: A Major Leap Forward

On August 14, 2025, Norgine announced that it has successfully completed the acquisition of Theravia, a prominent international pharmaceutical company specializing in therapies for patients suffering from rare and debilitating conditions. This strategic move represents a significant milestone for Norgine, as it strives to fulfill its mission of providing life-changing medicines to patients with unmet medical needs.

The closure of this acquisition sets the stage for Norgine to begin a structured integration process. This will involve aligning operations, systems, and teams to maximize efficiency and effectiveness in service delivery. Janneke van der Kamp, the Chief Executive Officer of Norgine, expressed enthusiasm about the completion of this acquisition, stating, "We are pleased about the successful closing of this acquisition as the addition of Theravia to our company further enhances our expertise in and growing portfolio of rare disease medicines."

With Theravia now operating as a wholly owned subsidiary of Norgine, the company solidifies its commitment to addressing the critical healthcare needs within Europe and the Australasian region (ANZ). The acquisition aligns with Norgine's growth strategy focused on enhancing access to vital products for patients in areas highlighted by significant medical needs, indicating strong potential for future impact in these markets.

Norgine has been a reputable player in the pharmaceutical industry, boasting over €550 million in annual revenues and a robust 120-year history of delivering transformative healthcare solutions. Its ingrained commitment to patient care has seen it develop a system of integrated operations that encompasses commercial capabilities along with deep medical, regulatory, and clinical expertise. This comprehensive infrastructure allows Norgine to swiftly deliver high-quality medicines to over 25 million patients globally each year.

The integration of Theravia is anticipated to bolster Norgine's capabilities further. With a focus on operational excellence, Norgine aims to continue pushing the boundaries of therapeutic innovation while ensuring that its products reach a broader patient base. This acquisition underscores Norgine's adaptability and commitment to meeting the evolving needs of healthcare.

Through its acquisition strategy, Norgine is positioned to continue building a legacy of over a century of innovation while remaining dedicated to doing the right thing for its patients. As the pharmaceutical landscape evolves, moves like this acquisition of Theravia exemplify how companies can align with the mission of providing essential healthcare solutions amidst growing demands for specific treatments for rare diseases.

In conclusion, Norgine's successful acquisition of Theravia is a testament to its relentless focus on expanding its product offerings and ensuring that they cater to patients who require specialized care. As the integration process unfolds, the pharmaceutical giant aims to enhance its healthcare services further, marking a new chapter for Norgine and positioning it to play an even more integral role in the global healthcare arena.

About Norgine

Norgine is a uniquely positioned specialty pharmaceutical and consumer healthcare company, known for its commitment to delivering life-changing products to patients and consumers. With its long-standing history, Norgine continues to innovate and push against the frontiers of therapeutic solutions, ensuring that medical needs are met effectively and expeditiously.